We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Gauging the 340B drug discount program’s effectiveness requires more price transparency and clearer guidance, expert witnesses told the Senate health committee Tuesday. Read More
In the latest development in the Michael Cohen-Novartis scandal, the U.S. Senate Committee on Finance pressured Novartis CEO Vasant Narasimhan for contracts and communications made between the pharma company and the president’s attorney. Read More
A federal appeals court affirmed the dismissal of a lawsuit brought by the nonprofit AIDS Healthcare Foundation (AHF) challenging Gilead’s patents on several of its HIV drugs. Read More
HHS Secretary Alex Azar offered more details on Monday of a plan that could expand Medicare’s ability to negotiate prices, implicitly responding to claims that the administration’s new drug pricing blueprint is too easy on drugmakers. Read More
Green was alleged to have acquired shares in Southwest for a nominal sum in exchange for a guaranteed “dividend” worth about $5,000 per month, as long as she referred a certain amount of urine drug screens. Read More